多中心前瞻性观察研究:特应性皮炎患者接受度普利尤单抗治疗相关眼部事件
该多中心前瞻性真实世界研究纳入181例接受度普利尤单抗治疗的成人特应性皮炎患者,第16周时34例(18.7%)出现度普利尤单抗诱导的睑结膜炎,其中32例为新发,27例基线结膜炎患者中25例改善。头颈部特应性皮炎、红皮病及基线干眼症为独立相关因素。
要点
- 第16周时34/181例(18.7%)出现度普利尤单抗诱导的睑结膜炎,其中27/34例(79.4%)为中度。
- 头颈部特应性皮炎(OR=7.254)和红皮病(OR=5.635)与睑结膜炎独立相关。
- 基线干眼症与睑结膜炎独立相关(OR=3.51)。
核心结论
- 本研究表明大多数度普利尤单抗诱导的睑结膜炎病例为新发。
- 本研究中未发现特应性皮炎严重程度和基线结膜炎为相关风险因素。
研究设计与样本
- 多中心、前瞻性、真实世界研究,纳入接受度普利尤单抗治疗的成人特应性皮炎患者181例。
主要发现
- 基线时27/181例(14.9%)患有结膜炎。
- 第16周时,27例基线结膜炎患者中25例改善、2例保持稳定。
- 第16周时34/181例(18.7%)出现度普利尤单抗诱导的睑结膜炎,其中新发32例、基础睑结膜炎加重2例。
- 大多数事件(27/34;79.4%)为中度。
- 多因素分析显示,头颈部特应性皮炎(OR=7.254;95%CI [1.938-30.07];p=0.004)、红皮病(OR=5.635;95%CI [1.635-21.50];p=0.007)和基线干眼症(OR=3.51;95%CI [3.158-13.90];p=0.031)是与度普利尤单抗诱导的睑结膜炎相关的独立因素。
关键数值与推荐
- 头颈部特应性皮炎:OR=7.254;95%CI [1.938-30.07];p=0.004。
- 红皮病:OR=5.635;95%CI [1.635-21.50];p=0.007。
- 基线干眼症:OR=3.51;95%CI [3.158-13.90];p=0.031。
- 第16周度普利尤单抗诱导的睑结膜炎发生率:34/181例(18.7%)。
- 睑结膜炎严重程度:中度27/34例(79.4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 随访期为16周,一些晚发的时间效应仍可能出现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. OBJECTIVE: To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events. METHODS: A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab. RESULTS: At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938-30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635-21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158-13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis. LIMITATIONS: Our follow-up period was 16 weeks and some late-onset time effects may still occur. CONCLUSION: This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.
引用
- Costedoat I, Wallaert M, Gaultier A, et al. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2023. PMID: 36732052. doi:10.1111/jdv.18932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。